roche pma interesting , page-58

don't know why you think that is so good?

DiaSorin (ds for short) thinks the world wide Immunoassay market is only Euro 7b. When Mix&Go becomes the gold standard glue in every test globally on a 10% royalty that means only Euro 700m in revenue to ADO.

I suppose if you add the 20% royalty on the Molecular diagnostics market you get another Euro 400m so ADO's revenue becomes Euro 1.1b.

Thats about $A1.45b so NPAT of about $A900m and on a PE of a modest 10x a market cap of around $9b or about $11 per share.

I'll just settle for the fully franked dividend of around $1 per share.







Please appreciate that I am only kidding. I don't seriously expect a dividend above 10c per share.

;)